Aciclovir does not reduce HIV acquisition in women or gay men with genital herpes

June 19, 2008

The antiviral drug aciclovir does not reduce HIV-1 acquisition in women or men who have sex with men with genital herpes. These are the conclusions of authors of an Article in this week's edition of The Lancet.

Across many observational studies, herpes simplex virus type-2 (HSV-2) infection, the most common cause of genital herpes, is associated with two-fold to three-fold increased risk for HIV-1 infection. Dr Connie Celum, University of Washington, Seattle, USA, and colleagues investigated whether HSV-2 suppression with aciclovir would reduce the risk of HIV-1 infection.

The researchers did a randomised, placebo-controlled phase III trial in HIV-negative, HSV-2 positive women in Africa and men who have sex with men (MSM) from sites in Peru and the USA. Participants received either aciclovir 400 mg (1637 patients) or placebo (1640) for 12-18 months, and were seen monthly for dispensation of study drug, adherence counselling and measurement by pill count and self-reporting, and risk reduction counselling; and every three months for genital examination and HIV testing. The primary outcome was HIV-1 infection and the secondary outcome was incidence of HSV-2 genital ulcers.

A total of 3172 participants (1358 women, 1814 MSM) were included in the analysis (1581 aciclovir, 1591 control). The incidence of HIV-1 was 3.9 per 100 person-years in the aciclovir group and 3.3 per 100 person-years in the placebo group -- thus the HIV incidence rates were not significantly different in the two groups. Incidence of genital ulcers was reduced by 47% in the aciclovir group, and incidence of genital ulcers confirmed to be due to HSV-2 was reduced by 63% in the aciclovir group. No serious adverse events were recorded in relation to aciclovir.

The authors conclude: "Our results show that suppressive therapy with standard doses of aciclovir is not effective in reduction of HIV-1 acquisition in HSV-2 seropositive women and MSM. Novel strategies are needed to interrupt interactions between HSV-2 and HIV-1." They add that additional studies will be needed to determine whether the lack of efficacy of aciclovir in reducing HIV acquisition and less than expected efficacy in reducing genital ulcers is due to drug absorption and metabolism, clinical response of genital ulcers to aciclovir, or persistent genital immune response after HSV-2 reactivation.

In an accompanying Comment, Professor Ronald Gray and Professor Maria Weaver, Johns Hopkins University, Baltimore, MD, USA, say that along with other evidence the study shows it is questionable as to whether control of sexually transmitted infections should be promoted specifically for HIV prevention in HIV-negative populations. They conclude: "Thomas Henry Huxley commented that 'The great tragedy of science â€" the slaying of a beautiful hypothesis by an ugly fact.' It is time to reassess the hypothesis and to adjust prevention policy accordingly."
-end-
Dr Connie Celum, University of Washington, Seattle, USA T) +1 206 520-3825 E) ccelum@u.washington.edu

Professor Ronald Gray and Professor Maria Weaver, Johns Hopkins University, Baltimore, MD, US T) +1 410 382 7581 / +1 410 955 7818 E) rgray@jhsph.edu

http://multimedia.thelancet.com/pdf/press/aciclovir.pdf

Lancet

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.